

## **CardioComm Solutions Inc. Announces Key Industry Acquisition**

**VICTORIA, B.C., January 31, 2007** – CardioComm Solutions Inc. (TSX-V:CCG) ("CardioComm", the "Company"), is pleased to announce that, subject to regulatory and shareholder approval, it will acquire all the issued and outstanding shares of CardioView, Inc. ("CardioView") on a share for share exchange. Specifically, CardioComm will issue 10,000,000 common shares, to a maximum value of \$600,000.00 to the shareholders of record at closing (approximately February 28<sup>th</sup>) in exchange for all the issued and outstanding shares of CardioView.

This acquisition will allow CardioComm to significantly increase and expand its product offerings. As CardioView has an established revenue base from research work done in Canada, CardioComm will expand the base and begin marketing the product in the US. The revenue model will become a user pay model similar to GlobalCardio™ – the 12 lead version will be launched this quarter in Canada and will be launched in the US in Q2, 2007.

Commenting on the acquisition, CardioComm CEO Stephen Martin added "This acquisition ensures that CardioComm will have the world's only commercially available web based stent reporting system which will be marketed along side GlobalCardio™ directly and through distribution channels. This is in line with the Company's strategic plan to dramatically increase revenue share and pay per use offerings which in turn will add to shareholder value".

The Company is also pleased to announce that Dr. Anatoly Langer, MD., M.Sc., FRCPC., FACC., Chair of the Canadian Heart Research Council, will join the Board of Directors upon regulatory approval of this acquisition. Dr. Anatoly was quoted as saying "Heart and vascular disease is responsible for more than half of all deaths and its management is of critical importance to patients and physicians. 12 lead ECG and coronary angiography are the most frequently used diagnostic procedures. Together CardioComm and CardioView will offer a unique and comprehensive solution for physicians and patients with access, storage, and diagnosis over the web. I am very excited to be part of this process. CHRC will be in excellent position to apply these innovative technologies to its research and educational activities."

### **About CardioView, Inc.**

CardioView, Inc. is a medical imaging and information technology company dedicated to improving communication and education in the field of cardiology. The Company is lead by a team of cardiologists, imaging scientists, programmers and web designers. Their premier product is a Web-enabled reporting system for interventional cardiologists. The system is in use across Canada.

CardioView's patented technology allows cardiologists to rapidly transmit high quality angiographic movies and procedural reports securely over the Web. For the first time, these movies are conveniently available anywhere, anytime for physicians and their patients. CardioView integrates seamlessly with existing systems at cardiac catheterization labs and is customizable for cardiologists, providing a highly affordable way to improve communication. CardioView has a ready solution for

cath labs wishing to advance cardiovascular care. In less than five minutes CardioView's patented technology allows cardiologists to create an enhanced diagnostic or PCI case report. Each report includes high quality angiographic movies which, along with diagrams and customizable clinical summaries, may be posted securely on the Web for referring physicians and their patients (if indicated by a cardiologist). The report can be printed for the chart or for your records: no more dictating, typing, drawing or calling.

**About CardioComm Solutions Inc.**

CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (ECGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time ECG viewer. CardioComm is the first company to provide a real-time means of viewing ECGs over a network (LAN, WAN or Internet). This tool enables ECGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global ECG Management System (GEMST<sup>™</sup>) and GlobalCardio<sup>™</sup>. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

**On behalf of the Board of Directors of CardioComm Solutions Inc.**

“Stephen Martin”

Stephen R. Martin, President & CEO

**For investor information, please contact:**

Stephen Martin

1-877-744-1122

[ir@cardiocomm.com](mailto:ir@cardiocomm.com)

*The TSX Venture Exchange has not reviewed and does not accept responsibility  
for the adequacy or accuracy of this release*